Suzuki S, Kawaguchi S, Ito K, Iwabuchi T
No Shinkei Geka. 1977 Jun;5(7):771-8.
The excellently low toxicity of a non-ionic watersoluble contrast medium Amipaque (Metrizamide), which is used for ventriculography, was confirmed by animal experiment and clinical application. In the animal experiment, 20 adult mongrel dogs were used and in each of them 1.5-5.0 ml of Amipaque was injected intraventriculary or intracisternally. As a result, we obtained a finding that the Amipaque is cleary safe compared with other watersoluble contrast media, espcially on epileptogenicity, while having an effect on the definition of picture and the nature of cerebrospinal fluid similar to other watersoluble contrast media. Thereafter, 14 ventriculographies were performed for 11 neurosurgical patients by using 4-10 ml of amipaque. Though one patient complained of a light headache after the examination, in no cases could convulsive complication be observed. The experience of this new medium gave us an impression that ventriculography with watersoluble contrast media will take the place of pneumoventriculography.
用于脑室造影的非离子型水溶性造影剂阿米培克（甲泛葡胺）毒性极低，这一点已通过动物实验和临床应用得到证实。在动物实验中，使用了20只成年杂种狗，每只狗脑室内或脑池内注射1.5 - 5.0毫升阿米培克。结果发现，与其他水溶性造影剂相比，阿米培克明显安全，尤其是在致癫痫性方面，同时在图像清晰度和脑脊液性质方面的效果与其他水溶性造影剂相似。此后，对11名神经外科患者进行了14次脑室造影，使用了4 - 10毫升阿米培克。尽管有一名患者在检查后抱怨轻微头痛，但未观察到惊厥并发症。这种新造影剂的使用经验给我们的印象是，水溶性造影剂脑室造影将取代气脑造影。
